Navigation Links
R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Date:9/10/2007

art 1 is to explore the effect of food on the pharmacokinetics of

R7128. Preliminary data from the single ascending dose portion of the

study indicate:

-- All doses of R7128 studied were generally safe and well-tolerated.

-- All patients completed the study, and none experienced

gastrointestinal adverse events or serious adverse events during

the study.

-- No hematological or laboratory abnormalities of clinical

significance were noted.

- Part 2 is a multiple ascending dose study of R7128 conducted in 40

patients chronically infected with HCV genotype 1 who have previously

failed interferon therapy. The primary objective of Part 2 is to

assess the safety, tolerability and pharmacokinetics of R7128 after

once-daily or twice-daily dosing for 14 days. The secondary objective

is to assess antiviral activity by measuring the change in HCV RNA.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The World Health Organization estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
9. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
10. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... ADELAIDE, Australia , April 17, 2015 ... the discovery and development of innovative therapeutics for the ... system, today announced the presentation of data from three ... American Association for Cancer Research (AACR) 106 th ... Philadelphia, PA USA. ...
(Date:4/16/2015)... , April 16, 2015  Hologic, Inc. ... cervical cancer screening study i published on-line ... peer-reviewed journal of the American Cancer Society. ... and the University of Pittsburgh Medical Center, supports current consensus ... recommend that women 30-65 years of age be ...
(Date:4/16/2015)... , April 16, 2015  Diplomat Pharmacy, Inc. ... Shannon Beltrand to their senior leadership team as ... be responsible for securing and properly monitoring Diplomat,s data, ... both internally and externally. Additionally, she will play key ... "We are very excited to have someone ...
Breaking Medicine Technology:Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 2Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 3Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 4Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 5Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 2Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 3Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 4Diplomat Names Shannon M. Beltrand as New CISO 2
(Date:4/18/2015)... 2015 On April 14th, 2015, Symantec released ... which they say, “exposes a tactical shift by cyberattackers.” With ... were introduced in 2014 - almost a million a day ... to be identified and patched by prominent manufacturers – as ... doing business in a digital world can be fraught with ...
(Date:4/18/2015)... 18, 2015 “ ArcAngel ” was featured ... a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... safety app. , In a turbulent world, people may ... 911 should always be their first move, but some situations ...
(Date:4/18/2015)... 18, 2015 French physician and gastronome ... choices when he uttered, “Tell me what you eat, ... food to cope with stress or sadness has often ... indicates otherwise. Data collected from their Emotional ... to emotional eating, but for different reasons. , Collecting ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 John Evans, ... Party on the Patio from 2 p.m. to 3 ... located at 1320 Executive Ct. in Pekin, Illinois, serves ... who need some help to maintain their independence. , ... and tropical treats will be served during the luau. ...
(Date:4/17/2015)... April 17, 2015 ERGO-Pedic Products, LLC, ... introducing two new products to help a broader range ... pain relief are the second most common visitors to ... product, designed specifically to help relieve sitting pain. Then, ... and thousands of happy customers later, we began getting ...
Breaking Medicine News(10 mins):Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2
... Reuters, the,world,s leading source of intelligent information for ... Pharma KOLexperts, a,new solution designed to help pharmaceutical ... opinion leaders,(KOLs) and scientific experts. It is the ... to rank life sciences KOLs with a range ...
... Oct. 14 Katherine O. McCary, of,Midlothian, Virginia, ... serve as,a member of the National Council on ... Ms. McCary,s nomination on October 2, 2008., ... Banks, Inc. and reports to,the Chairman, President and ...
... DC OCTOBER 14, 2008 Late-breaking ... Prevent Radio Contrast Nephropathy in Patients Undergoing ... during the 20th annual Transcatheter Cardiovascular Therapeutics ... Research Foundation (CRF). , The prospective, ...
... digestive illnesses should have levels monitored, study says , , ... bowel disease or chronic liver disease may be at ... says. , Vitamin D is essential in the body,s ... role in a person having strong, healthy bones. , ...
... ... DIEGO, Oct. 14 The American Council on Exercise,(ACE), America,s ... education and training organizations in the world,today announced key findings ... Crosse through its exercise and health program,on the benefits of ...
... Pharmaceuticals, LLC, a,privately held, specialty pharmaceutical company ... today announced that it has,acquired North American ... from Crown Laboratories, Inc. This agreement expands ... chronic dermatologic,conditions including scalp psoriasis and seborrheic ...
Cached Medicine News:Health News:Thomson Reuters Launches Thomson Pharma KOLexperts(R) to Help the Pharmaceutical Industry Objectively Identify, Verify and Rank Scientific Experts, Product Advocates, Clinical Investigators and Key Opinion Leaders 2Health News:Midlothian Resident Katherine McCary Appointed by President Bush to National Council on Disability 2Health News:Late-breaking results of clinical trial on therapeutic endovascular cooling reported at TCT 2008 2Health News:IBD, Liver Disease Patients Show Vitamin D Deficits 2Health News:American Council on Exercise (ACE) Studies Impact of Boot Camp-Style Workouts 2Health News:Avidas Pharmaceuticals Signs Agreement to Acquire North American Rights to Products That Address Chronic Dermatologic Conditions 2
... BioZip Suture Anchor is a unique double loaded ... is made from Poly-L Lactic Acid (PLLA) and ... are attached to the suture ends for open ... repairs. The trocar tip inserter allows insertion with ...
... LactoSorb copolymer is an absorbable ... L-Lactic acid and 18% glycolic acid. ... such as 100% poly-L-lactic acid (PLLA) ... copolymer is substantially amorphous (without crystallinity), ...
... is an absorbable co-polymer synthesized from ... 18% glycolic acid. Unlike the homopolymers ... poly-L-lactic acid (PLLA) or 100% poly-glycolic ... amorphous (without crystallinity), meaning that its ...
... The USS Sports Medicine™ POLYSORB™ Soft Tissue Anchor ... to attach soft tissue to bone using sutures. ... prepared hole in the bone, and is used ... are made of a resorbable copolymer, derived from ...
Medicine Products: